Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 September 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2023Published: 27 February 2013
Tirzepatide for treating type 2 diabetes (TA924)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2022
Faricimab for treating diabetic macular oedema (TA799)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Sotagliflozin with insulin for treating type 1 diabetes (TA622)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2020
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 23 November 2016Published: 26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2016
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2008
Diabetic retinopathy - ruboxistaurin [ID382]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes [ID1450]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes [ID1451]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sotagliflozin for treating type 2 diabetes [ID1657]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin icodec for treating type 2 diabetes [ID6175]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [TSID12131]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Orforglipron for treating type 2 diabetes [TSID12130]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC